Guardant Health
Yahoo Finance • 6 days ago
Top Specialty Lab Stocks to Watch This Earnings Season, According to BTIG
Investing.com-- Several specialty lab companies are set to report third-quarter results in early November, with analysts at BTIG outlining key metrics and expectations for the sector's leading names. The firm has identified three stocks po... Full story
Yahoo Finance • 15 days ago
Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?
A Cancer Test Approval Meets a High Valuation Guardant Health, Inc. (NASDAQ:GH) is moving beyond identifying mutations at diagnosis toward testing patients repeatedly as their cancer changes. Recent FDA approval of Guardant360 CDx as a co... Full story
Yahoo Finance • 16 days ago
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases of $25.9M of CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), $24.4M of Meta Platforms (META [https://seek... Full story
Yahoo Finance • 18 days ago
Is Guardant Health (GH) At A Turning Point After Its Patent Setback?
Guardant Health (NasdaqGS:GH) lost a key U.S. patent challenge after the PTAB upheld all 30 claims of TwinStrand's '127 patent. The ruling centers on Duplex Sequencing technology and follows an earlier jury finding of willful patent infrin... Full story
Yahoo Finance • 20 days ago
3 of Wall Street’s Favorite Stocks That Fall Short
3 of Wall Street's Favorite Stocks That Fall Short The stocks in this article have caught Wall Street's attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt... Full story
Yahoo Finance • 27 days ago
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographies This latest approval marks Guardant's 31st CDx approval PALO ALTO, Calif., October 08, 2026--(BUSINESS WIRE)--G... Full story
Yahoo Finance • 29 days ago
Dow Jones Future Fall After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys, But These Stocks Slammed
The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys. Continue Reading... Full story
Yahoo Finance • last month
These IBD 50 Stocks Are Stalled. That Could Be A Good Thing.
A few IBD 50 stocks are showing unusually narrow trading. Continue Reading... Full story
Yahoo Finance • last month
Coverbase Adds Third-Party Risk Veterans as Enterprise Adoption Accelerates
Coverbase Brian Shaw and Constantine Malaxos join as enterprise customers expand across financial services, healthcare, and technology SAN FRANCISCO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Coverbase, AI engineered for third-party risk manage... Full story
Yahoo Finance • last month
Cathie Wood Makes a Big AI Bet and Cuts Bitcoin Exposure
This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a notable shift inside its technology portfolio last week, adding heavily to CoreWeave while cutting several other AI and technology positions. Ark bought about 239,... Full story
Yahoo Finance • 2 months ago
Dow Jones Futures Rise As Oil Prices, Yields Fall Before Fed Rate Hike; Will Market Rally Bid Bond Voyage?
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision? Continue Reading... Full story
Yahoo Finance • 2 months ago
Dow Jones Futures Rise As ServiceNow, Twilio Lead 8 New Buys; How Will Bonds React To Fed Hike?
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision? Continue Reading... Full story
Yahoo Finance • 2 months ago
Dow Jones Futures Rise; ServiceNow, Twilio Lead New Buys As Fed Hike Looms
The S&P 500 and Nasdaq undercut key support as oil prices and Treasury yields jumped. How will bonds react to the Federal Reserve decision. Continue Reading... Full story
Yahoo Finance • 2 months ago
Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says
Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the re PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 2 months ago
1 Growth Stock to Add to Your Roster and 2 We Turn Down
1 Growth Stock to Add to Your Roster and 2 We Turn Down Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COV... Full story
Yahoo Finance • 2 months ago
What Makes Guardant Health (GH) a Compelling Bet?
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the "Artisan Mid Cap Fund". The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March low... Full story
Yahoo Finance • 2 months ago
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
Approval recommends repeat Guardant360 CDx testing every three months during therapy to detect emerging ESR1 mutations before clinical or radiographic disease progression In the Phase III SERENA-6 trial, ctDNA-guided treatment using Guarda... Full story
Yahoo Finance • 2 months ago
Ten healthcare stocks leading in year-over-year CapEx growth
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthca... Full story
Yahoo Finance • 2 months ago
Guardant ordered to pay $245m in DNA sequencing patent dispute
A US court has ordered Guardant Health to pay TwinStrand Biosciences and the University of Washington (UW) $245.2m after upholding a November 2023 jury verdict that found the company liable for infringing on patented DNA sequencing technol... Full story
Yahoo Finance • 2 months ago
Palantir, Freeport Clear Buy Points, Lead Five Stocks To Watch
Freeport-McMoRan and Palantir scored breakouts Friday, leading five stocks near buy points from a variety of sectors. Continue Reading... Full story